Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
Burgess
Elisabeth P
EP
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000379:methods; D004341:Drug Evaluation / Q000379:methods; D004335:Drug and Narcotic Control; D005260:Female; D006801:Humans; D009520:New Zealand; D010344:Patient Advocacy; D000068878:Trastuzumab; D016896:Treatment Outcome; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab